Stockscreener 앱 받기
60.96
2.25%
1.34
Royalty Pharma Plc 주식(RPRX)의 최신 뉴스
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Zacks Investment Research
Royalty Pharma EVP Marshall Urist sells $235,594 in shares - Investing.com
Form 4 Royalty Pharma Plc For: 12 October By Investing.com - Investing.com Nigeria
Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again - Zacks Investment Research
At $57.10 a share, Royalty Pharma (RPRX) EVP Marshall Urist sells 4,126 shares. - Stock Titan
Officer Marshall Urist proposes selling 4,126 Royalty Pharma (RPRX) shares. - Stock Titan
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com Nigeria
Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com South Africa
Royalty Pharma EVP Marshall Urist sells $238,812 in shares - Investing.com
Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com Canada
Royalty Pharma EVP Marshall Urist sells $238,812 in shares By Investing.com - Investing.com India
Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com UK
A director acquires 642 shares in lieu of a $37,500 retainer at Royalty Pharma (RPRX). - Stock Titan
4,126 shares sold under a trading plan by Royalty Pharma (RPRX) EVP Marshall Urist. - Stock Titan
Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com Nigeria
Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com Canada
Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com South Africa
Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com UK
Royalty Pharma officer proposes $239K share sale | RPRX SEC FilingForm 144 - Stock Titan
Form 144 Royalty Pharma PLC For: 27 September By Investing.com - Investing.com Nigeria
Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com India
Royalty Pharma EVP Christopher Hite sells $5.85m in shares By Investing.com - Investing.com Canada
Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com Nigeria
Royalty Pharma EVP Christopher Hite sells $5.85m in shares - Investing.com
Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com Canada
Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com UK
Royalty Pharma EVP Christopher Hite sells $5.85m in shares By Investing.com - Investing.com UK
Royalty Pharma plc (RPRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Royalty Pharma (RPRX) holder plans new sale after selling 350,000 shares - Stock Titan
Royalty Pharma PLC $RPRX Shares Sold by Corient Private Wealth LP - MarketBeat
Could Royalty Pharma’s (NASDAQ:RPRX) Story Be Changing Fast? - kalkinemedia.com
Royalty Pharma PLC $RPRX Shares Sold by National Pension Service - MarketBeat
Tidal Investments LLC Has $6.63 Million Holdings in Royalty Pharma PLC $RPRX - MarketBeat
(RPRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
California State Teachers Retirement System Increases Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Wall Street Zen Upgrades Royalty Pharma (NASDAQ:RPRX) to Strong-Buy - MarketBeat
Engineers Gate Manager LP Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure? - Yahoo Finance
Squarepoint Ops LLC Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma to present at Morgan Stanley global healthcare investor conference - Bitget
Royalty Pharma to present at upcoming investor conferences - marketscreener.com
Royalty Pharma to Present at Upcoming Investor Conferences - Moomoo
Royalty Pharma PLC $RPRX Shares Sold by C WorldWide Group Holding A S - MarketBeat
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today - Benzinga
TD Cowen raises Royalty Pharma stock price target on unchanged growth outlook - Investing.com Nigeria
Royalty Pharma (NASDAQ:RPRX) Shares Gap DownWhat's Next? - MarketBeat
RPRX Maintained by TD Cowen -- Price Target Raised to $68.00 - GuruFocus
TD Cowen raises Royalty Pharma stock price target on unchanged growth outlook - Investing.com India
TD Cowen raises Royalty Pharma stock price target on unchanged growth outlook - Investing.com UK
1.50%
자본화:
|
볼륨(24시간):